MOOR INSTRUMENTS LIMITED

Company number 02209367 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Credit Analysis: Moor Instruments Limited

1. Credit Opinion: CONDITIONAL

Reasoning: Moor Instruments presents a mixed credit profile. On the positive side, the company is long-established (incorporated 1987), operates in a specialist biomedical niche, carries virtually no debt (£126k total liabilities), and maintains substantial net assets of £1.92M. However, the financial trajectory is clearly negative — net assets have declined 45% from their 2023 peak of £3.5M, with significant losses evident in FY2024 (~£776k) and FY2026 (~£730k). Cash reserves have fallen from £2.28M (2022) to £473k (2026), an alarming 79% reduction. A recent management transition — with founder and majority shareholder name shown to subscribers resigning as director and chairman in November 2025 — adds further uncertainty. Any credit facility should be conditional on understanding the drivers behind recent losses, the new management's turnaround plan, and the quality and realisability of the £1.16M stock position.

2. Financial Strength

Balance Sheet Analysis:

The balance sheet remains fundamentally sound in structure, though deteriorating:

Metric FY2022 FY2024 FY2026 Trend
Net Assets £3,261,282 £2,729,541 £1,920,054 Declining
Cash £2,280,105 £784,317 £472,833 Declining sharply
Total Liabilities £186,956 £139,032 £126,058 Stable/low
Share Capital — — £500,071 Unchanged

Key observations: - Very low leverage: Total liabilities of £126k against net assets of £1.92M means the company is essentially debt-free. This provides significant balance sheet cushion. - P&L reserve erosion: The profit and loss reserve has fallen from £2,064,932 (FY2025) to £1,335,236 (FY2026), confirming a loss of approximately £730k for the year. This follows a similar loss in FY2024. - Stock concentration risk: Stock of £1,157,668 now represents approximately 56% of total assets (£2.06M). This is a material concentration. If this inventory is slow-moving, obsolete, or specialised biomedical equipment with limited secondary market value, the true net asset position could be weaker than reported. - Fixed assets minimal: Only £52,689 in fixed assets, indicating the business is not capital-intensive and has limited tangible security to offer. - Share capital of £500,071 (with called-up share capital noted as £584,789 in capital data) provides a reasonable equity base.

Balance Sheet Quality Concern: The heavy stock weighting and declining cash position suggest the business may be burning through reserves while inventory is not converting to sales efficiently. The debtors position has also halved year-on-year (£684k → £373k), which could indicate declining sales volumes.

3. Cash Flow Assessment

Liquidity Position:

Metric FY2025 FY2026 Change
Cash £1,019,521 £472,833 -£546,688
Current Assets £2,830,670 £2,003,548 -£827,122
Current Liabilities £234,184 £126,058 -£108,126
Net Current Assets £2,596,486 £1,877,490 -£718,996

Working capital remains nominally strong at £1.88M, but this is heavily skewed towards stock (£1.16M). The liquid component (cash + debtors) is £846k, which still comfortably covers current liabilities of £126k — a current ratio of approximately 15.9x. However, this ratio is somewhat misleading given the stock-heavy composition.

Cash burn trajectory: The company has consumed approximately £1.81M of cash over four years (from £2.28M in FY2022 to £473k in FY2026). At the most recent year's burn rate of ~£547k, the remaining cash would be exhausted within approximately 10 months without intervention. However, this assumes no revenue generation, which is unrealistic for an operating business.

Debt service capacity: With no existing debt obligations, any new facility would be the company's first external borrowing. The minimal current liabilities suggest capacity to take on modest debt, but the loss-making trajectory raises questions about ability to service repayments from operations.

Provisions: Small provision of £10,125 — not material.

4. Monitoring Points

Critical metrics to track:

  1. Return to profitability: The company must demonstrate a path to profit. Two years of ~£750k losses in a three-year period is unsustainable. Request management accounts for the current trading period to assess whether FY2027 is tracking differently.

  2. Stock turnover and inventory quality: With £1.16M tied up in stock (56% of total assets), understanding inventory age, turnover ratios, and obsolescence risk is essential. Request a stock aging analysis. If significant portions are obsolete or slow-moving, a write-down could further erode net assets.

  3. Cash runway: Monitor monthly cash position closely. The current £473k provides limited buffer if losses continue. Establish a minimum cash covenant if a facility is extended.

  4. Management transition stability: name shown to subscribers (founder, 50-75% shareholder) and other long-standing directors resigned in November 2025. New directors name shown to subscribers and name shown to subscribers are now in place. Assess their experience, track record, and strategic plan. Determine whether the founder's departure represents orderly succession or signals deeper issues.

  5. Sales trajectory: The halving of debtors (£684k → £373k) may indicate a significant revenue decline. Request turnover figures and order book data, which are not visible in the filed accounts under the small company exemption.

  6. Dividend or extraction activity: Investigate whether the equity erosion is purely operational losses or whether there have been distributions to shareholders during the decline period.

  7. PSC and ownership structure: name shown to subscribers retains 50-75% ownership despite resigning as director. Clarify whether he remains involved informally and whether any shareholder loans or related-party transactions exist.

  8. Filing compliance: Accounts are filed on time (next due January 2028 for FY2026 accounts). Confirmation statement is current. No compliance concerns at present.

Facility structuring recommendations if approved: - Limit exposure to a proportion of the stock or debtors position, not the full net asset value - Require quarterly management accounts - Establish minimum cash and net worth covenants - Consider personal guarantees from the majority shareholder (name shown to subscribers) given his ongoing equity interest - Short initial term with review points to assess turnaround progress

Names of the people mentioned are shown to subscribers. See subscription

Perspective: Business Credit Analyst · Model: glm-5.2 · Generated 17 October 2026